ALNYLAM PHARMACEUTICALS, INC. Stock Issued During Period, Value, Other
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, other for the quarter ending 2019-03-31 was $784.00K, a 38.27% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, other for the quarter ending 2018-03-31 was $567.00K.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, other for fiscal 2018 was $8.98M, a 52.11% increase from fiscal 2017.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, other for fiscal 2017 was $5.91M, a 61.92% increase from fiscal 2016.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, other for fiscal 2016 was $3.65M, a 36.83% increase from fiscal 2015.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, other for fiscal 2015 was $2.67M, a 68.63% increase from fiscal 2014.
| Period end | Stock Issued During Period, Value, Other 3 month | Stock Issued During Period, Value, Other 12 month |
|---|---|---|
| 2019-03-31 | $784.00K 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $8.98M 10-K · filed 2019-02-14 | |
| 2018-03-31 | $567.00K 10-Q · filed 2019-05-02 | |
| 2017-12-31 | $5.91M 10-K · filed 2019-02-14 | |
| 2016-12-31 | $3.65M 10-K · filed 2019-02-14 | |
| 2015-12-31 | $2.67M 10-K · filed 2018-02-15 | |
| 2014-12-31 | $1.58M 10-K · filed 2017-02-15 | |
| 2013-12-31 | $1.18M 10-K · filed 2016-02-12 | |
| 2012-12-31 | $879.00K 10-K · filed 2015-02-13 | |
| 2011-12-31 | $1.02M 10-K · filed 2014-02-20 | |
| 2010-12-31 | $2.42M 10-K · filed 2013-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |